MYGN has been the topic of several other reports. Zacks Investment Research raised shares of Myriad Genetics from a hold rating to a buy rating and set a $36.00 price objective on the stock in a research note on Wednesday, July 27th. Mizuho decreased their price objective on shares of Myriad Genetics from $34.00 to $22.00 and set a neutral rating on the stock in a research note on Wednesday, August 10th. Barclays PLC reaffirmed an overweight rating and set a $50.00 price objective on shares of Myriad Genetics in a research note on Wednesday, July 6th. Wells Fargo & Co. raised shares of Myriad Genetics from a market perform rating to an outperform rating in a research note on Sunday, August 21st. Finally, TheStreet cut shares of Myriad Genetics from a buy rating to a hold rating in a research note on Wednesday, August 10th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. Myriad Genetics presently has a consensus rating of Hold and a consensus target price of $31.00.
Shares of Myriad Genetics (NASDAQ:MYGN) traded up 0.16% on Monday, hitting $18.90. The company had a trading volume of 438,223 shares. Myriad Genetics has a 12-month low of $18.58 and a 12-month high of $46.24. The company has a 50 day moving average of $20.90 and a 200-day moving average of $29.84. The company has a market cap of $1.31 billion, a price-to-earnings ratio of 11.05 and a beta of 0.54.
Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, August 9th. The company reported $0.36 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.38 by $0.02. The business earned $186.50 million during the quarter, compared to the consensus estimate of $187.95 million. Myriad Genetics had a net margin of 14.98% and a return on equity of 16.06%. The business’s revenue was down 1.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.41 EPS. On average, analysts forecast that Myriad Genetics will post $1.07 earnings per share for the current year.
In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the stock in a transaction on Monday, September 12th. The shares were sold at an average price of $20.49, for a total value of $614,700.00. Following the sale, the director now directly owns 49,493 shares in the company, valued at $1,014,111.57. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Christopher Capone bought 10,000 shares of the business’s stock in a transaction on Friday, August 19th. The stock was purchased at an average price of $21.24 per share, for a total transaction of $212,400.00. Following the completion of the acquisition, the insider now owns 146,026 shares of the company’s stock, valued at approximately $3,101,592.24. The disclosure for this purchase can be found here. 5.80% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of MYGN. Emerald Acquisition Ltd. purchased a new stake in Myriad Genetics during the second quarter valued at $27,284,000. Rice Hall James & Associates LLC bought a new stake in shares of Myriad Genetics during the second quarter valued at about $16,101,000. River Road Asset Management LLC bought a new stake in shares of Myriad Genetics during the second quarter valued at about $12,259,000. First Eagle Investment Management LLC bought a new stake in shares of Myriad Genetics during the second quarter valued at about $11,291,000. Finally, Numeric Investors LLC increased its stake in shares of Myriad Genetics by 586.6% in the second quarter. Numeric Investors LLC now owns 409,200 shares of the company’s stock valued at $12,522,000 after buying an additional 349,600 shares in the last quarter.
Myriad Genetics Company Profile
Myriad Genetics, Inc (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing, or assess a patient’s risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.